Published in Am Heart J on October 01, 2006
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34
ICD programming. Indian Heart J (2013) 2.00
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail (2014) 0.83
Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis. J Interv Card Electrophysiol (2008) 0.75
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med (2008) 4.65
Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol (2004) 4.44
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
What causes sudden death in heart failure? Circ Res (2004) 3.44
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35
Mechanisms of sudden cardiac death. J Clin Invest (2005) 2.90
Fragmented QRS on a 12-lead ECG: a predictor of mortality and cardiac events in patients with coronary artery disease. Heart Rhythm (2007) 2.37
Inaccessibility to quinidine therapy is about to get worse. J Am Coll Cardiol (2013) 2.12
The QT syndromes: long and short. Lancet (2008) 2.10
Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol (2003) 1.95
Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol (2005) 1.92
Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm (2005) 1.83
Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol (2008) 1.80
Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res (2014) 1.64
Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation (2008) 1.62
The DAVID (Dual Chamber and VVI Implantable Defibrillator) II trial. J Am Coll Cardiol (2009) 1.60
Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol (2003) 1.59
Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation (2011) 1.58
Spontaneous electrocardiogram alterations predict ventricular fibrillation in Brugada syndrome. Heart Rhythm (2011) 1.51
Heart rate-corrected QT interval in men increases during winter months. Heart Rhythm (2006) 1.48
Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length. J Cardiovasc Electrophysiol (2002) 1.44
Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Am Heart J (2002) 1.43
Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome. Cardiovasc Res (2007) 1.40
Fragmented QRS: a predictor of mortality and sudden cardiac death. Heart Rhythm (2008) 1.38
Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a postinfarction heart failure canine model. Circulation (2005) 1.34
Task Force 7: arrhythmias. J Am Coll Cardiol (2005) 1.30
Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation (2011) 1.27
Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J (2003) 1.21
Pulseless electric activity: definition, causes, mechanisms, management, and research priorities for the next decade: report from a National Heart, Lung, and Blood Institute workshop. Circulation (2013) 1.18
Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol (2001) 1.16
Risk stratification for sudden cardiac death: a plan for the future. Circulation (2014) 1.14
Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation (2009) 1.14
Cardiology patient page. Catheter ablation of arrhythmias. Circulation (2002) 1.12
Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J (2009) 1.10
Prophylactic lidocaine in acute myocardial infarction: resurface or reburial? Am J Cardiol (2004) 1.06
Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation (2006) 1.05
Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation (2013) 1.04
Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol (2002) 1.04
A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial). Circ Cardiovasc Interv (2009) 1.03
Temperature modulation of ventricular arrhythmogenicity in a canine tissue model of Brugada syndrome. Heart Rhythm (2006) 1.01
Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther (2002) 1.01
Effects of thoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol (2002) 1.01
Mechanisms of sinoatrial node dysfunction in a canine model of pacing-induced atrial fibrillation. Heart Rhythm (2009) 1.00
Functional and transmural modulation of M cell behavior in canine ventricular wall. Am J Physiol Heart Circ Physiol (2004) 0.99
[Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary]. Rev Esp Cardiol (2006) 0.96
Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm (2009) 0.96
Antiarrhythmics Versus Implantable Defibrillators (AVID)--rationale, design, and methods. Am J Cardiol (1995) 0.95
Psychosocial status predicts mortality in patients with life-threatening ventricular arrhythmias. Heart Rhythm (2007) 0.94
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.94
Epicardial but not endocardial premature stimulation initiates ventricular tachyarrhythmia in canine in vitro model of long QT syndrome. Heart Rhythm (2004) 0.93
Attitudes of law enforcement officers regarding automated external defibrillators. Acad Emerg Med (2002) 0.93
Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol (2003) 0.92
Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST)and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID). Control Clin Trials (2003) 0.91
Task Force 10: automated external defibrillators. J Am Coll Cardiol (2005) 0.91
Short-term rapid atrial pacing produces electrical remodeling of sinus node function in humans. J Cardiovasc Electrophysiol (2002) 0.89
Optical mapping of the functional reentrant circuit of ventricular tachycardia in acute myocardial infarction. Heart Rhythm (2004) 0.89
The end-of-study patient survey: methods influencing response rate in the AVID Trial. Control Clin Trials (2002) 0.89
Mortality as an endpoint in atrial fibrillation. Heart Rhythm (2004) 0.88
Intrathecal clonidine reduces the incidence of ischemia-provoked ventricular arrhythmias in a canine postinfarction heart failure model. Heart Rhythm (2005) 0.88
Two simple questions to assess neurologic outcomes at 3 months after out-of-hospital cardiac arrest: experience from the public access defibrillation trial. Resuscitation (2010) 0.88
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.88
Epicardial ablation eliminates ventricular arrhythmias in an experimental model of Brugada syndrome. Heart Rhythm (2009) 0.87
Device therapy to modulate the autonomic nervous system to treat heart failure. Curr Cardiol Rep (2012) 0.87
Effect of surgical revascularization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry. Am Heart J (2002) 0.86
T wave alternans in an in vitro canine tissue model of Brugada syndrome. Am J Physiol Heart Circ Physiol (2006) 0.86
Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. J Cardiovasc Pharmacol (2010) 0.86
Genes and cardiac repolarization: the challenge ahead. Circulation (2005) 0.85
Repolarization heterogeneity in the right ventricular outflow tract: correlation with ventricular arrhythmias in Brugada patients and in an in vitro canine Brugada model. Heart Rhythm (2008) 0.85
Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation (2002) 0.84
Location of cardiac arrests in the public access defibrillation trial. Prehosp Emerg Care (2006) 0.82
Apparent protective effect of increased left ventricular wall thickness in an ICD population. J Card Fail (2003) 0.82
Mechanisms of disease: new mechanisms of antiarrhythmic actions. Nat Clin Pract Cardiovasc Med (2004) 0.82
Coronary occlusion and reperfusion promote early afterdepolarizations and ventricular tachycardia in a canine tissue model of type 3 long QT syndrome. Am J Physiol Heart Circ Physiol (2005) 0.82
Rate-dependent [K+](o) accumulation in canine right atria in vivo: electrophysiological consequences. Am J Physiol Heart Circ Physiol (2002) 0.82
Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm (2004) 0.82
Ischemic ventricular arrhythmias during heart failure: a canine model to replicate clinical events. Heart Rhythm (2005) 0.82
Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries. J Am Coll Cardiol (2013) 0.82
Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol (2011) 0.81
Differences in arrhythmogenicity between the canine right ventricular outflow tract and anteroinferior right ventricle in a model of Brugada syndrome. Heart Rhythm (2006) 0.81